Cormedix Inc. (CRMD)
NASDAQ:CRMD
Want to see CRMD full AI Analyst Report?
CRMD Stock Chart & Stats
$7.39
$0.06(0.58%)
At close: 4:00 PM EST
$7.39
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$6.13 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.42M
Market Cap
$691.95M
Enterprise Value$646.98M
Total Cash (Recent Filing)$178.09M
Total Debt (Recent Filing)$144.88M
Price to Earnings (P/E)3.7
Beta1.60
Next Earnings
Aug 06, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding78,451,890
10 Day Avg. Volume1,357,090
30 Day Avg. Volume1,415,158
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit1.88
Enterprise Value/Ebitda3.04
Forecast
1Y Price Target
$14.25Price Target Upside92.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.51
Revenue Forecast (FY)$332.71M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & MarginsSustained high margins and near‑one-to-one cash conversion provide durable internal funding for commercial expansion, R&D, and buybacks. Over a 2–6 month horizon this strengthens financial flexibility, lowers refinancing needs, and supports reinvestment without immediate external capital.
DefenCath Commercial Traction And Large CustomersClear uptake at major dialysis providers creates recurring unit demand and entrenchment in clinical practice. Large customer run‑rate gains and published real‑world support reduce execution risk for core product revenues and underpin a steady addressable market over coming quarters.
REZZAYO Phase III Success Expands PipelineTopline Phase III success and planned sNDA create a credible regulatory path and a potential new hospital prophylaxis franchise. This diversifies revenue beyond catheter locks, increasing long‑term addressable market and reducing single‑product concentration risk if approval and commercialization proceed.
Bears Say
TDAPA Expiration & Reimbursement RiskA payer reimbursement transition creates structural revenue timing and pricing risk: patient utilization may remain but unit economics could deteriorate during CMS add‑on conversion. This threatens sustainable net selling price and short‑to‑medium term cash flow visibility until new reimbursement is established.
Higher Leverage After Prior Low-debt PeriodMaterial debt accumulation versus prior minimal leverage raises structural financial risk if margins revert. Even with current strong ROE, higher interest or covenants could constrain flexibility for M&A, R&D, or pricing support, making earnings persistence critical to avoid liquidity stress.
TPN (NUTRI‑GAURD) Phase III Enrollment DelaysSlower enrollment and pushed timelines delay potential label expansion and associated revenue diversification. Extended development timelines increase trial costs and execution risk, deferring upside from TPN and concentrating near‑term reliance on DefenCath and REZZAYO outcomes.
Cormedix News
CRMD FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was $6.13 and its highest was $17.43 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is $691.95M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 44 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on May 14, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.343 by $0.087.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.23.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 78,451,890 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of $0.43 in its last earnings report, beating expectations of $0.343. Following the earnings report the stock price went up 5.733%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (92.83% Upside)
$14.25 (92.83% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 327.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.19%
12-Months-Change
Fundamentals
Return on Equity
50.38%
Trailing 12-Months
Asset Growth
445.27%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: large Q1 revenue and adjusted EBITDA beats, raised full‑year guidance, successful REZZAYO Phase III top‑line results with near‑term regulatory path, and solid cash generation. Offsetting risks include near‑term reimbursement variability from TDAPA expiry affecting H2 2026, a nonrecurring $9M revenue adjustment, mark‑to‑market charges, and a delayed TPN Phase III timeline pushing that program into 2028. On balance the positive execution, guidance increases, pipeline progress (REZZAYO) and strong balance sheet outweigh the highlighted challenges.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$14.25
▲(92.83% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.91% Insiders
10.35% Mutual Funds
17.83% Other Institutional Investors
55.95% Public Companies and Individual Investors